# LP10X - Hybrid Investment Platform Rivalling VC Scale Returns - Adriana Tortajada, CEO & Managing Partner, 1200 VC

An episode of [VC10X - Investing, Venture Capital, Asset Management, Family Office, Wealth Management](https://invisiblenetwork.ai/podcast/1632806986), 9 Jul 2024, 53 min.

Audio: https://anchor.fm/s/a453ddd4/podcast/play/89028756/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2024-6-9%2F33a7b76c-be34-bc9f-1492-28996315a5bd.mp3

Adriana Tortajada is the CEO & Managing Partner at 1200 VC, an Early-Stage investment platform that invests in fund managers and founders shaping the future of humanity. Its focus is on seeking transformative technologies and regional value creation, which will accelerate a positive impact on the planet and society. She is a pioneer in the venture capital industry across Mexico and Latin America, and a Kauffman Fellow, Adriana has managed $1B+ in Fund investments as well as bringing 20+ years of experience empowering the venture capital ecosystem. We talk about: - Unique hybrid model of investing - What they look for in GPs - How long it takes to make an LP commitment after the first meeting? - Do spinouts make good fund managers? - How should fund managers think about sizing the fund - Promising VC scale returns - Perspective on the current exit market & lots more Links: ⭐ Sponsored by Podcast10x - Podcasting agency for VCs - https://podcast10x.com 1200 VC - https://1200.vc Adriana Tortajada on LinkedIn - https://www.linkedin.com/in/adriana-tortajada-2784869b 🎙️ Hosted by Prashant Choubey Follow Prashant on X - https://x.com/ChoubeySahab Follow Prashant on LinkedIn - https://www.linkedin.com/in/choubeysahab Email - prashantchoubey3@gmail.com Subscribe to VC10X on Youtube - https://youtube.com/@vc10x VC10X is available on Spotify, Apple Podcasts & YouTube.

Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them.